NCT01386112View on ClinicalTrials.gov

Safety and Tolerability Study of Oral EUR-1100 to Treat Eosinophilic Esophagitis

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

October 31, 2012

Study Completion Date

October 31, 2012

Conditions
Eosinophilic Esophagitis
Interventions
DRUG

EUR-1100

Active oral medication

DRUG

placebo

matching placebo

Trial Locations (7)

19104

University of Pennsylvania, Philadelphia

22030

O&O Alpan LLC Center for Clinical Trials, Fairfax

30342

Children's Center for Digestive Health, Atlanta

46202

Riley Hospital for Children, Indianapolis

55905

Mayo Clinic, Rochester

60611-2951

Northwestern University School of Medicine, Chicago

08330

South Jersey Pediatric Gastroenterology, Mays Landing

Sponsors
All Listed Sponsors
lead

Forest Laboratories

INDUSTRY